secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lifeward Ltd. (LFWD)
CIK:        0001607962
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001178913-26-001106
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifeward posts Q4 revenue $5.1M (-33% YoY); enters Oramed deal for oral insulin platform
--------------------------------------------------------------------------------

- Q4 revenue $5.1M (-33% YoY); full year $22.0M (-14% YoY). ReWalk exoskeleton sales +20% in Q4.
- Net loss narrowed 65% to $5.3M ($3.60/share) in Q4; full year $19.9M ($17.16/share).
- GAAP gross margin 38.2% in 2025 (non-GAAP 40.9%); operating expenses down 25%.
- Cash $2.2M at Dec 31, 2025; expects up to $47M funding from Oramed upon closing strategic deal.
- Shareholders approved Oramed deal: Lifeward acquires POD oral insulin tech; Oramed gets up to 49.99% equity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607962/000117891326001106/0001178913-26-001106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607962/000117891326001106/zk2634859.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-001106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer